New Biomarker Impact on HCV Therapy and Clinical Trials
It's extraordinarily rare for a biomarker discovery to have a fast, clear-cut, and significant impact on a therapeutic area. But recent findings from a hepatitis C study--that a specific genetic variation strongly correlates with response to standard interferon-based therapy--could influence decision-making on when and how to treat certain HCV patients. What's more, the research may influence the design of clinical trials of new HCV agents and even trials in other diseases treated with interferon.
You may also be interested in...
Two Phase III hepatitis C protease inhibitors from Vertex and Schering are set to reshape treatment for a difficult disease and potentially capture a significant chunk of a large and growing market. But other new therapies and combination regimens aren't far behind.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
The device giant is recalling Cobalt and Crome defibrillators because they may deliver weaker shocks than intended.